Regulus Therapeutics Inc

Regulus Therapeutics — Investor Presentation (October 2021)

36 slides from Regulus Therapeutics's investor presentation, Oct 18, 2021

  1. Slide 1: Corporate Presentation - October 2021

    Corporate Presentation - October 2021 Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program, including

  3. Slide 3: Regulus Investment Highlights

    Regulus Investment Highlights Leading microRNA Co leveraging novel technology into first-in-class therapeutics Expertise in microRNA biology/oligo chemistry based on company founding via JV between Ionis & Alnylam Platform optimized to deliver oligonucleotide therapies to the kidney Clinical pipelin

  4. Slide 4: Innovative Pipeline: Primary Focus on Kidney Diseases

    Innovative Pipeline: Primary Focus on Kidney Diseases Target Validation Lead Optimization IND enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome lademirsen* ADPKD** RGLS8429 Research Programs Other Research Programs*** *Formerly RG-012 **Autosomal Dominant Polycystic Kidney Disease *** CNS,

  5. Slide 5: Lademirsen (RG-012): Alport Syndrome

    Clinical demonstration of desired kidney exposure & binding of target, miR-21 Lademirsen (RG-012): Alport Syndrome Partnered with Sanofi Achieved $10m milestone in 2020 Regulus eligible to receive $25M milestone upon successful completion of Phase 2 Attractive safety profile to date: Chronic treatme

  6. Slide 6: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Autosomal Dominant Polycystic Kidney Disease (ADPKD) Orphan disease and high unmet medical need Kidney Function Decline by Age The Underlying Pathology Mutation of either Pkd1 or Pkd2 genes causes formation and proliferation of fluid-filled cysts in the kidneys leading to loss of kidney function ove

  7. Slide 7: ADPKD: Orphan disease and high unmet medical need

    Autosomal Dominant Polycystic Kidney Disease (ADPKD) Orphan disease and high unmet medical need 85% 160K patients with Pkd1 mutation diagnosed individuals in U.S. Patient population 50% patients develop ESRD by age 60 Health Burden $3.8B+ estimated annual cost of renal replacement therapy in U.S.1 1

  8. Slide 8: Limitations of Standard of Care: Jynarque

    Jynarque® (tolvaptan, vasopressin V2 antagonist) – FDA approved April 2018 Boxed warning due to potentially fatal liver injury & failure requiring transplant REMS program with restricted distribution & ongoing liver monitoring in patients Despite limitations, 2020 sales were $694M in US (2021 est. $

  9. Slide 9: ADPKD Pathology

    ADPKD Pathology Increased miR-17 expression Represses target gene expression (Pkd1 and Pkd2) Decreases PC1 and PC2 protein levels Mutations in Pkd1 and Pkd2 genes

  10. Slide 10: ADPKD Pathology: Inhibiting miR-17

    ADPKD Pathology Inhibits miR-17 function De-represses Pkd1 and Pkd2 gene expression Increases PC1 and PC2 protein levels Mutations in Pkd1 and Pkd2 genes Treatment with anti-miR17 uELV = urinary exosome-like vesicle Significant increase in PC1 and PC2 measured in uELVs

  11. Slide 11: Pathway to Target Validation

    Pathway to Target Validation Disease Association Genetic Validation Pharmacologic Validation Biomarker Validation

  12. Slide 12: miR-17 is Upregulated in ADPKD models

    miR-17 is Upregulated in ADPKD models Mouse kidney cysts & human ADPKD cyst cells Human Kidney Samples In-situ hybridization Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 Normal Human Kidney ADPKD Kidney miR-17 probe miR-17 probe Control probe Control probe Mouse Kidney Samples qPCR analysis Nor

  13. Slide 13: miR-17 Directly Binds Pkd1 & Pkd2 Genes Mediating ADPKD

    miR-17 Directly Binds Pkd1 & Pkd2 Genes Mediating ADPKD 3’UTRs of Pkd1 and Pkd2 contain conserved miR-17 binding sequences miR-17 mimic represses Pkd1 and Pkd2 in mouse collecting duct (IMCD3) cells PNAS 2013 June;110(26): 10765-10770 WT: wildtype 3’UTR MT: mutated 3’UTR Pkd1: 3’UTR conserved bindin

  14. Slide 14: Kidney-specific Knockdown of miR-17~92 Cluster Attenuates disease

    Kidney-specific Knockdown of miR-17~92 Cluster Attenuates disease in ADPKD mouse model (Pkd1F/RC) Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 MRI Imaging c: Serum Creatinine d: % Proliferation based on number of pHH3+ proliferating cyst epithelial cells Disease Association Genetic Validation P

  15. Slide 15: Restoration of Pkd2 Expression is Disease-Modifying in ADPKD

    Dong et al, Nature Genet 2021; https://doi.org/10.1038/s41588-021-00946-4 Tamoxifen treatment starting at 13w increases PC2 expression in genetically-engineered mouse model of ADPKD and reverses cyst formation Restoration of pkd2 Expression is Disease-Modifying in ADPKD Recent Publication Showed Dis

  16. Slide 16: First Gen Compound (RGLS4326) confers efficacy in Pkd1F/RC mouse model

    First Gen Compound (RGLS4326) treatment confers efficacy in Pkd1F/RC mouse model of ADPKD Lee et al. (2021) PKD-Connect; Poster Presentation KW = kidney weight; BW = Body weight Pkd1F/RC mice were dosed s.c. with RGLS4326 or Control Oligo at 20 mg/kg on post-natal day (P)8, 10, 12 and 15 and sacrifi

  17. Slide 17: First Gen Compares Favorably to Standard of Care

    15w (sacrifice) First Gen Compares Favorably to Standard of Care Efficacy in the Pcy/DBA Mouse Model Age: 6w 14w Pcy/DBA: Tolvaptan (Chow; ad libitum) RGLS4326 (QW) Lee et al., (2019)10:4148 Nat. Comm. Disease Association Genetic Validation Pharmacologic Validation Biomarker Validation

  18. Slide 18: First Gen Slows Cystic Expansion

    First Gen Slows Cystic Expansion Efficacy in the Pcy/DBA mouse model Stabilization Reduction Reduction Magnetic Resonance Imaging Lee et al., (2019)10:4148 Nat. Comm. Changes in body-weight adjusted total kidney volume (bwTKV) from baseline at week 8, 11 and 14 was significantly reduced after RGLS43

  19. Slide 19: Urinary Biomarker Assay Can Detect PC1 and PC2 in Humans

    Urinary Biomarker Assay Can Detect PC1 and PC2 in Humans Protein levels correlated with disease severity Lower levels of PC1 and PC2 are associated with disease severity based on increased kidney size Preliminary analysis support sample size (n=9) sufficient to detect ~45% and ~70% increase in PC1 a

  20. Slide 20: First Gen treatment Increases Polycystin Levels In Vitro

    First Gen treatment Increases Polycystin Levels In Vitro Achieved by binding miR-17 and derepressing Pkd1 and Pkd2 Gene Expression (RNA) (Protein) Lee et al. (2021) PKD-Connect; Poster Presentation Disease Association Genetic Validation Pharmacologic Validation Biomarker Validation

  21. Slide 21: First Gen Demonstrated Significant Increase in Key Biomarkers in Patients

    First Gen Demonstrated Significant Increase in Key Biomarkers in Patients with ADPKD Lee et al. (2021) PKD-Connect; Poster Presentation Significant increase in urinary PC1 and PC2 were observed at the end of the study (D71) compared to baseline (p=0.004 and p=0.026, respectively, based on paired t-t

  22. Slide 22: First Gen (RGLS4326) Summary

    First Gen (RGLS4326) Summary Statistically significant increase in key biomarkers (polycystin 1 & 2) demonstrated in patients with ADPKD in short term study at 1 mg/kg Polycystin levels inversely correlated with disease severity and restoring expression has been shown to reverse disease in animal mo

  23. Slide 23: Next Gen (RGLS8429) Overview

    Next Gen (RGLS8429) Overview

  24. Slide 24: RGLS8429: Next Generation Anti-miR-17 for ADPKD

    RGLS8429: Next Generation Anti-miR-17 for ADPKD Next Steps: IND-enabling activities near complete with IND and initiation of Phase 1 expected in Q2 2022 Completed: non-GLP toxicity studies at 2-3x higher dose levels with no similar dose-limiting toxicity signs Succeeded in designing new compound wit

  25. Slide 25: RGLS8429 does not Inhibit AMPA Glutamate Receptors

    RGLS8429 does not Inhibit AMPA Glutamate Receptors (AMPA-R): Absence of CNS-like Toxicities seen with RGLS4326 *[3H] AMPA ligand binding to synaptic membranes from rat cerebral cortex. Whole-cell patch-clamp studies in HEK293 cells overexpressing rGluA1 or rGluA2 in response to 3mM Glutamate. Unpubl

  26. Slide 26: RGLS8429 Significantly More Tolerable than RGLS4326 in Toxicity Studies

    Next-gen RGLS8429 Shown to be Significantly More Tolerable than RGLS4326 in Preclinical Toxicity Studies Dotted Lines Indicate Cumulative Exposure with No CNS-like adverse events

  27. Slide 27: RGLS8429 has Similar In-Vitro Potency to miR-17 Compared to RGLS4326

    RGLS8429 has Similar In-Vitro Potency to miR-17 Compared to RGLS4326 Mouse Cells Human Cells Normal Kidney Cells ADPKD Cells RGLS4326 IC50=77nM* RGLS8429 IC50=168nM *Lee et al., (2019)10:4148 Nat. Comm. RGLS4326 IC50=48nM RGLS8429 IC50=56nM RGLS4326 IC50=93nM RGLS8429 IC50=82nM RGLS4326 IC50=17nM RG

  28. Slide 28: RGLS8429 has Similar PK profile Compared to RGLS4326

    RGLS8429 has Similar PK profile Compared to RGLS4326 with Preferential Kidney Exposure and Long Half-Life in Tissue *Lee et al., (2019)10:4148 Nat. Comm. *

  29. Slide 29: RGLS8429 has similar PD profile compared to RGLS4326

    RGLS8429 has similar PD profile compared to RGLS4326 *Lee et al., (2019)10:4148 Nat. Comm. * *

  30. Slide 30: RGLS8429 has similar efficacy in Pkd1F/RC mouse model

    RGLS8429 has similar efficacy in Pkd1F/RC mouse model of ADPKD compared to RGLS4326 Pkd1F/RC mice were dosed SC with PBS or 20 mg/kg of designated oligos on post-natal days (P)8, 10, 12, 15 and euthanized at P18 PBS Control Oligo RGLS8429 RGLS4326

  31. Slide 31: RGLS8429 Demonstrated Potent Efficacy as low as 1mg/kg

    RGLS8429 Demonstrated Potent Efficacy in Pkd1F/RC mouse model of ADPKD as low as 1mg/kg Pkd1F/RC mice were dosed SC with PBS, control oligo at 20 mg/kg, or RGLS8429 at 1, 5 or 20 mg/kg on post-natal days (P)8, 10, 12, 15 and euthanized at P18. Another group of mice were dosed SC with RGLS8429 at 20m

  32. Slide 32: RGLS8429 Combined with Tolvaptan Demonstrated Enhanced Efficacy

    RGLS8429 Dosed in Combination with Tolvaptan in Pcy/DBA mouse model Demonstrated Enhanced Overall Efficacy Profile* Tolvaptan is the only approved therapy for patients with ADPKD Market Penetration has been slow due to significant warnings and monitoring as well as overall tolerability Anti-miR17 th

  33. Slide 33: RGLS8429 Proposed Clinical Program

    RGLS8429 Proposed Clinical Program

  34. Slide 34: Proposed Interleaf Design Enables Rapid Path to Proof-of-Mechanism

    Proposed Interleaf Design Enables Rapid Path to Potential Proof-of- Mechanism in Patients with APDKD 0.5 mg/kg 4.0 mg/kg 8.0 mg/kg 0.5 mg/kg 1.0 mg/kg 2.0 mg/kg Single Dose Arm 2.0 mg/kg Multiple Dose Arm Healthy Volunteers 8 / cohort Single Dose with 14day f/u Randomized 3:1 Safety and PK ADPKD Pat

  35. Slide 35: Anticipated Milestones

    Anticipated Milestones Catalyst Potential Timing Pre-IND Meeting for next-gen RGLS8429 Q4 2021 IND Submission and Initiation of Phase 1 Study for RGLS8429 Q2 2022 Top-line Data from First Cohort of Patients in Phase 1b MOA Study Early 2023

  36. Slide 36: Corporate Presentation- October 2021

    Corporate Presentation- October 2021

Regulus Therapeutics — Investor Presentation (October 2021) on 6ix